252 related articles for article (PubMed ID: 32111923)
1. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Sartor O; Armstrong AJ; Ahaghotu C; McLeod DG; Cooperberg MR; Penson DF; Kantoff PW; Vogelzang NJ; Hussain A; Pieczonka CM; Shore ND; Quinn DI; Small EJ; Heath EI; Tutrone RF; Schellhammer PF; Harmon M; Chang NN; Sheikh NA; Brown B; Freedland SJ; Higano CS
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):517-526. PubMed ID: 32111923
[TBL] [Abstract][Full Text] [Related]
2. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Schellhammer PF; Chodak G; Whitmore JB; Sims R; Frohlich MW; Kantoff PW
Urology; 2013 Jun; 81(6):1297-302. PubMed ID: 23582482
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW; Higano CS; Shore ND; Berger ER; Small EJ; Penson DF; Redfern CH; Ferrari AC; Dreicer R; Sims RB; Xu Y; Frohlich MW; Schellhammer PF;
N Engl J Med; 2010 Jul; 363(5):411-22. PubMed ID: 20818862
[TBL] [Abstract][Full Text] [Related]
5. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
Zagars GK; Pollack A; Pettaway CA
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
Halabi S; Armstrong AJ; Sartor O; de Bono J; Kaplan E; Lin CY; Solomon NC; Small EJ
J Clin Oncol; 2013 Nov; 31(31):3944-50. PubMed ID: 24101043
[TBL] [Abstract][Full Text] [Related]
9. Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.
Underwood W; Wei J; Rubin MA; Montie JE; Resh J; Sanda MG
Urol Oncol; 2004; 22(1):20-4. PubMed ID: 14969799
[TBL] [Abstract][Full Text] [Related]
10. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.
Omlin A; Pezaro C; Mukherji D; Mulick Cassidy A; Sandhu S; Bianchini D; Olmos D; Ferraldeschi R; Maier G; Thompson E; Parker C; Attard G; de Bono J
Eur Urol; 2013 Aug; 64(2):300-6. PubMed ID: 23313031
[TBL] [Abstract][Full Text] [Related]
11. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma.
Verma PS; Howard RS; Weiss BM
Am J Hematol; 2008 May; 83(5):355-8. PubMed ID: 18186525
[TBL] [Abstract][Full Text] [Related]
12. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Hwang C; Henderson NC; Chu SC; Holland B; Cackowski FC; Pilling A; Jang A; Rothstein S; Labriola M; Park JJ; Ghose A; Bilen MA; Mustafa S; Kilari D; Pierro MJ; Thapa B; Tripathi A; Garje R; Ravindra A; Koshkin VS; Hernandez E; Schweizer MT; Armstrong AJ; McKay RR; Dorff TB; Alva AS; Barata PC
JAMA Netw Open; 2023 Sep; 6(9):e2334208. PubMed ID: 37721753
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
[TBL] [Abstract][Full Text] [Related]
15. Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history.
Mandal DM; Sartor O; Halton SL; Mercante DE; Bailey-Wilson JE; Rayford W
Prostate Cancer Prostatic Dis; 2008; 11(3):274-9. PubMed ID: 18268528
[TBL] [Abstract][Full Text] [Related]
16. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
Quinn DI; Vaishampayan U; Higano CS; Lin DW; Shore ND; Beer TM
Expert Rev Anticancer Ther; 2014 Jan; 14(1):51-61. PubMed ID: 24224900
[TBL] [Abstract][Full Text] [Related]
17. Statewide analysis of serum prostate specific antigen levels in Louisiana men without prostate cancer.
Kyle C; Ewing T; Wu XC; Mercante D; Lifsey D; Meunier C; Jefferson L; Sartor O; Rayford W
J La State Med Soc; 2004; 156(6):319-23. PubMed ID: 15688673
[TBL] [Abstract][Full Text] [Related]
18. Racial disparities in survival after diagnosis of prostate cancer in Kentucky, 2001-2010.
Antwi S; Tucker TC; Coker AL; Fleming ST
Am J Mens Health; 2013 Jul; 7(4):306-16. PubMed ID: 23339130
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
[TBL] [Abstract][Full Text] [Related]
20. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.
Pettaway CA; Lamerato LE; Eaddy MT; Edwards JK; Hogue SL; Crane MM
BJU Int; 2011 Oct; 108(8):1302-8. PubMed ID: 21371244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
